PROPEL: A phase 1/2 trial of NKTR-214 (CD122-biased agonist) combined with anti-PD-1 (pembrolizumab) or anti-PD-L1 (atezolizumab) in patients (pts) with advanced solid tumors.

Daniel A. Vaena, James K. Schwarz, Nicholas J. Vogelzang et al.|Journal of Clinical Oncology|2018

Cited by 3